Company Overview and News
(Reuters) - Lithium producer Livent Corp (LTHM.N) fell 3.6 percent in its market debut on Thursday after being priced at the lower end of its expected range, as investors worried about the recent declines in prices of lithium in China, the world’s largest consumer of the ultralight metal.
LTHM FTI.WI FMC
Livent Corp. LTHM, +0.00% priced its initial public offering at $17 a share, the company said late Wednesday. The price of $17 for 20 million shares was below the $18- to $20-a-share range the lithium company had previously said it expects and is now set to raise $340 million. BofA Merrill Lynch, Goldman Sachs and Credit Suisse Securities are acting as joint book-running managers. The underwriters have the option to purchase up to 3 million additional shares.
(Reuters) - The initial public offering of lithium producer Livent Corp was priced at $17 per share on Wednesday, lead bookrunner Bank of America Merrill Lynch said, below a target range and giving the company a market value of $2.43 billion.
FTI.WI FMC DTK
The electric-battery metal is trading at its lowest levels in two years. After doubling in 2016 and rising another third last year, lithium carbonate swap prices for Asia are down 30 per cent so far this year, according to Benchmark Mineral Intelligence.
GTIJY ALB GUOTF FTI.WI FMC
2018-10-07 247wallst - 2
Last week’s initial public offering (IPO) action saw eight companies launch successful offerings that raised $1.57 billion in new capital. Half of the IPOs were completed by blank-check companies. A total of five IPOs are scheduled to launch in the coming week seeking a total of $1.06 billion in new capital.
FTI.WI FMC DTK EDTX GH ESTC UPWK KOD ARYAU EDTXU MS ARYA
2018-10-06 seekingalpha - 4
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
MMS STZ.B PSX WBA ACRX AEE EGC EXXIQ IMGN SBLK WU SODA GPRE EEXXQ UTX EXXI REX SHLDW ADM MLM NIO SHIP QTT HALO LB NVDA MPC BRO ATVI KO BWXT EA SJM INPAP KBR MA DK JPM SBUX GVA WMT LEAF SHLD IP AMZN OMF EXIXQ OMC SAFM BKS YI POL SQ SBLKL INCY FAST BKE STZ SB GME WEB GOOGL PNC CURO ZUO WFCNP PG DAR TRVN GLOP PYPL GS GOGL AVEO WEED DAL WFC MGI C CMCSA COST FMC THO CGC GNK V T PEP FLR SNE TELL
Sept 27 (Reuters) - Albemarle Corp, the world’s largest lithium producer, aims to eventually end its dependence on two smaller units to fund growth as global appetite surges for electric-powered vehicles and consumer goods, its chief executive said in an interview.
VLKAF ALB FTI.WI FMC
NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Piedmont Lithium Limited (“Piedmont” or “Company”) is pleased to report the results of the Company’s updated Scoping Study for its vertically-integrated Piedmont Lithium Project (“Project”) located within the Carolina Tin-Spodumene Belt in North Carolina, USA (“TSB”). The Project includes a lithium hydroxide chemical plant (“Chemical Plant”) supplied with spodumene concentrate from an open pit mine and concentrator (“Mine/Concentrator”).
PDDTF LTUM ALB FTI.WI FMC
BOSTON (Reuters) - Hedge fund Tide Point Capital Management is shutting down due to the majority owner’s personal wishes, the latest casualty in the $3 trillion industry which has faced increasing challenges in raising money and delivering top returns, two sources with knowledge of the move said on Wednesday.
JEC KORS FTI.WI FMC MS CMG
The market could have ended Tuesday’s action on either side of the fence, but when push came to shove as the closing bell approached, the big 11.5% advance from Advanced Micro Devices (NASDAQ:AMD) just wasn’t enough to offset all the other losers. Though the S&P 500 only lost 0.17% of its value yesterday, decliners outnumbered advancers by almost two-to-one.
NKE FMC TSLA AMD LLY HPE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to FMC / FMC Corp. on message board site Silicon Investor.
as of ET